

# Interim Report

MeVis Medical Solutions AG H1-2023/2024



**MeVis**

# TABLE OF CONTENTS

<b>FOREWORD BY THE EXECUTIVE BOARD .....</b>	<b>2</b>
<b>THE MEVIS SHARE .....</b>	<b>3</b>
<b>INTERIM MANAGEMENT REPORT H1 2023/2024.....</b>	<b>4</b>
Preliminary Note .....	4
company Basics.....	4
Organization.....	4
Brief overview of business activities.....	4
Economic report.....	5
Business performance .....	5
Earnings situation .....	5
Net assets and financial position.....	5
Opportunity and risk report .....	6
Forecast report .....	6
<b>BALANCE SHEET .....</b>	<b>7</b>
<b>PROFIT AND LOSS ACCOUNT .....</b>	<b>9</b>
<b>APPENDIX .....</b>	<b>10</b>
Basic information .....	10
General information .....	10
Accounting and valuation methods .....	10
Selected notes to the balance sheet and income statement.....	10
1. Receivables and other assets.....	10
2. Provisions.....	10
3. Liabilities.....	11
4. Accruals and deferred income .....	11
5. Sales revenue.....	11
6. Other operating income .....	11
7. Personnel expenses .....	11
8. Other operating expenses .....	11
9. Relationships with related parties .....	11
Supplementary report .....	12
<b>ASSURANCE OF THE LEGAL REPRESENTATIVE .....</b>	<b>13</b>
<b>DISCLAIMER .....</b>	<b>14</b>

## FOREWORD BY THE EXECUTIVE BOARD

*Dear readers,*

In the first half of the year, the company's revenue amounted to € 8,774 k (previous year: € 8,472 k). Of this figure, 27% (previous year: 26%) is attributable to the sale of licenses, 35% (previous year: 35%) to maintenance revenue and 38% (previous year: 39%) to other revenue, which includes services for and recharges to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) rose from € 1,893 k to € 2,735 k, which corresponds to an EBIT margin of 24%, mainly due to the lower expenses from currency translation compared to the previous year.

As in the first six months of the previous year, business in Mammography Diagnostics developed more positively in the first half of 2024. In line with our forecast, more licenses were sold, which is attributable to the renewed increase in demand. The maintenance business in Mammography Diagnostics remained stable compared to the previous year. In addition, other sales in the area of mammography diagnostics also developed better than in the same period of the previous year. The cooperation with our customer Hologic continues to be very positive.

The sales trend in the area of lung cancer screening solutions paints a varied picture. Due to process changes by our OEM customers when ordering licenses, we are unfortunately behind the previous year in terms of orders for our lung CAD algorithms. In the marketing of our stand-alone and cloud-based Veolity solutions, we are slightly ahead of the previous year in terms of license sales, but below our expectations. We are seeing increasing demand for commercial use in the early detection of lung cancer. Unfortunately, however, we are finding that tenders continue to be delayed, which means that orders and implementation are also being delayed. The market outlook for comprehensive lung cancer screening remains very positive and it is noticeable that more medical technology companies are looking at solutions for lung cancer screening and bringing products onto the market.

Solutions in the field of liver surgery continued to develop very positively in the past six months. Following the market launch of MeVis' own software application and in addition to the growing services in the area of technical visualization of the liver, which MeVis has been providing for many years, we have a positive outlook for the second half of the year. Thanks to increased marketing and sales activities and the approval of the liver surgery software application in the USA, which is very important for us, we see increasing potential in this area. In the future, we will increasingly expand our activities to large markets such as the Middle East and India.

At this point in time, we are sticking to our forecast: for the 2023/2024 financial year, sales are now expected to increase slightly year-on-year to between € 18.0 m and € 18.5 m. In addition to the slight increase in sales with the customer Hologic, sales in the lung and liver area are also expected to increase slightly. We expect a slight decline in the area of development services. For earnings before interest and taxes (EBIT), we expect stability in the range of € 4.5 m to € 5.0 m. The forecast slight growth in sales and the simultaneous increase in personnel costs and other operating expenses are key drivers for the EBIT outlook.

As in the previous reporting period, the Management Board will regularly review its expectations over the course of the 2023/2024 financial year on the basis of current business developments.



Marcus Kirchhoff  
Executive Board Member

## THE MEVIS SHARE

AS OF 31.03.2024	
ISIN / WKN / Ticker Symbol	DE000A0LBFE4 / A0LBFE / M3V
Industry classification	Software / Medical technology
signed Share capital	€ 1,820,000,00
Number of shares	1,820,000
Last price fixing on 29.09.2023	€ 28.40
Last price fixing on 28.03.2024	€ 25.00
Highest/lowest price in 2023/2024	€ 28.20 / € 23.20
Market capitalization	€ 45,500 million
General Standard (Regulated Market)	Frankfurt and Xetra
Regulated unofficial market	Berlin, Dusseldorf, Munich, Stuttgart
Indices	CDAX, General All-Share, DAXsector All Software

### SHARE PRICE DEVELOPMENT

From October 1, 2023 to March 31, 2024, the MeVis Medical Solutions AG share price developed with a slightly negative trend around an average price level of € 25.00. At the beginning of the fiscal year, the share was quoted at € 28.20 and closed at € 25.00 in Xetra trading at the end of March. Over the course of the first half of fiscal year 2023/2024, the share price reached a high of € 28.20 and a low of € 23.20 in Xetra trading. Compared to € 35.80 at the end of March 31, 2023, the value of the MeVis share has fallen by 35 % in twelve months. As at the reporting date of March 28, 2024, the market capitalization thus amounted to approximately € 46 million, taking into account 1,820,000 shares in circulation.

### SHAREHOLDER STRUCTURE AS AT MARCH 31, 2024

As of the balance sheet date, 73.66 % of the total share capital of MeVis Medical Solutions AG was held by Varex Imaging Deutschland AG, an indirect subsidiary of Varex Imaging Corporation, Salt Lake City, Utah, USA. According to the shareholder notifications received by us, another institutional shareholder is HANSAINVEST Hanseatische Investment-GmbH, which holds approx. 12.57 % of the total share capital of MeVis Medical Solutions AG. This means that around 13.77 % of the shares are in free float.

### COMPENSATION PAYMENT

The domination and profit and loss transfer agreement between Varex Imaging Deutschland AG and MMS AG obliges Varex Imaging Deutschland AG to pay the outside shareholders a recurring cash payment ("compensation payment") for each full financial year for the duration of this agreement. This amounts to € 1.13 (gross) or € 0.95 (net) per share for each full financial year.

# INTERIM MANAGEMENT REPORT H1 2023/2024

## PRELIMINARY NOTE

This report covers the first half of the 2023/2024 financial year, i.e. the reporting period from October 1, 2023 to March 31, 2024. The prior-year amounts stated below relate to the first half of the 2022/2023 financial year from October 1, 2022 to March 31, 2023. MeVis Medical Solutions AG prepared its annual financial statements for the 2022/2023 financial year in accordance with the provisions of the German Commercial Code (HGB) applicable to corporations and in compliance with the German Stock Corporation Act (AktG). These interim financial statements were also prepared on this basis.

## COMPANY BASICS

### ORGANIZATION

MeVis Medical Solutions AG (hereinafter also referred to as "MMS AG", "MeVis" or the "Company") was founded in 1997 and commenced operations in 1998. 73.66 % of the share capital of MMS AG is currently held by Varex Imaging Deutschland AG, Willich. There is a control and profit and loss transfer agreement between Varex Imaging Deutschland AG as the controlling company and MeVis Medical Solutions AG as the controlled company. Through Varex Imaging Deutschland AG, MMS AG thus belongs to the Varex Group under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

At the end of fiscal year 2022/2023, MMS AG held 51 % of the shares in MeVis BreastCare GmbH & Co. KG, Bremen, (hereinafter also referred to as "MBC KG") as part of a joint venture with Siemens Healthcare GmbH, Munich. At the end of October 1, 2023, Varex Imaging Deutschland AG acquired all shares held by Siemens Healthcare GmbH, Munich, and 2 % of the shares held by MMS AG in the joint venture. Since October 2, 2023, MMS AG has thus held 49 % of MeVis BreastCare GmbH & Co. KG, Bremen, as part of a joint venture with Varex Imaging Deutschland AG.

### BRIEF OVERVIEW OF BUSINESS ACTIVITIES

MeVis Medical Solutions AG develops innovative software for recording, analyzing and evaluating image data and markets it to manufacturers of medical devices, providers of medical IT platforms and, to a lesser extent, directly to clinical end customers.

The clinical focus is on image-based early detection and diagnosis of epidemiologically significant diseases, such as breast, lung and liver diseases. The software solutions support many of the imaging procedures used. These include not only X-ray-based radiography procedures such as computed tomography, mammography or digital tomosynthesis, but also magnetic resonance imaging, digital sonography and the simultaneous use of several procedures (multimodality). MeVis supplies technologies and software applications for global market leaders in the medical sector that meet these companies' requirements for technological leadership and help them to expand their position.

In addition to the sale of software licenses and associated maintenance contracts, MeVis also offers software programming services for medical technology companies as development services. These include project processing by software development teams consisting of software developers, product and project managers, application specialists and test engineers. The teams support external customers in the development of software modules or applications and in the integration of new functions and new technologies, such as algorithms based on artificial intelligence. Services are also provided to clinical end customers. These include three-dimensional technical visualizations ("MeVis Distant Services"), interactive online training to improve clinicians' diagnostic skills and Internet-based special applications in teleradiology ("MeVis Online Services").

While in the early years of MeVis the focus was on image-based early detection and diagnosis of breast cancer, today MeVis uses the clinical expertise it has acquired, its know-how in the field of breast cancer, its innovative

software technologies and the partner network it has built up to successively develop its software solutions for new applications in other indications and diseases of other parts of the body.

## ECONOMIC REPORT

### BUSINESS PERFORMANCE

The company's operating business consists of the development and sale of software licenses, the associated maintenance business, software programming for medical technology companies (development services) and the provision of services for technical visualizations (distant services) as well as online training.

At around 89 % (previous year: 87 %) of total sales, the software business, which includes products for the medical technology company Hologic, once again accounted for the majority of the company's total sales in this reporting period.

The first half of the 2023/2024 financial year was once again successful for MeVis in terms of key financial figures. The company continued to benefit from Hologic's very good market position for breast cancer screening.

### EARNINGS SITUATION

In the first half of the year, the company's revenue amounted to € 8,774 k (previous year: € 8,472 k). The sale of licenses accounted for 27 % of sales (previous year: 26 %), maintenance sales for 35 % (previous year: 35 %) and other sales for 38 % (previous year: 39 %), which include services for and recharges to affiliated companies and the parent company. The slight improvement in license sales is mainly attributable to the business with Hologic. The deterioration in other sales compared to the previous year is due to a reduction in sales in the area of development services.

Other operating income amounted to € 652 k in the first half of the year (previous year: € 626 k). This mainly comprises income from exchange rate differences in the amount of € 531 k (previous year: € 568 k).

The cost of materials increased slightly to € 250 k (previous year: € 208 k). The company's personnel expenses amounted to € 5,073 k in the first half of the year (previous year: € 4,739 k). In the reporting year, the average number of permanent employees at the company rose by 3 to 111.

Other operating expenses amounted to € 1,947 k in the reporting period (previous year: € 2,834 k). They consist of expenses from exchange rate differences of € 742 k (previous year: € 1,739 k), rental expenses of € 259 k (previous year: € 252 k), expenses for legal, consulting and auditing services of € 228 k (previous year: € 217 k), selling expenses of € 106 k (previous year: € 129 k), operating expenses of € 59 k (previous year: € 64 k) and other operating expenses of € 560 k (previous year: € 433 k).

Earnings before interest and taxes (EBIT) rose from € 1,893 k to € 2,735 k, mainly due to lower expenses from currency translation compared to the previous year.

Income from loans of financial assets amounted to € 643 k (previous year: € 624 k) and is attributable to interest income from the loan granted to Varex Imaging Deutschland AG. This results in earnings before taxes (EBT) of € 2,735 k (previous year: € 1,893 k).

Income taxes of € 74 k (previous year: € 64 k) were incurred in the past half year, therefore, taking into account the expenses from the profit to be transferred to Varex Imaging Deutschland AG in the amount of € 2,661 k (previous year: € 1,829 k), net income for the year amounted to € 0 k (previous year: € 0 k). It should be noted that the expense from the profit transfer does not legally arise until the end of the financial year.

### NET ASSETS AND FINANCIAL POSITION

Total assets decreased to € 25,131 k (Sep 30, 2023: € 28,054 k). Current assets decreased by € 3,152 k, while equity remained constant. Provisions decreased by € 692 k and liabilities decreased by € 2,322 k. Deferred income increased by € 92 k.

The equity ratio increased to 71% (Sep 30, 2023: 64%) due to the lower balance sheet total and constant equity, while the gearing ratio fell accordingly to 29% (Sep 30, 2023: 36%).

Current assets decreased by € 3,152 k to € 8,174 k as at the balance sheet date (Sep 30, 2023: € 11,326 k). This is mainly due to the decrease in trade receivables from € 2,652 k to € 2,355 k and the decrease in cash and cash equivalents (cash in hand, bank balances) from € 7,744 k to € 4,872 k.

The company's equity remained constant at € 17,826 k (Sep 30, 2023: € 17,826 k) and, in addition to the subscribed capital of € 1,820 k (Sep 30, 2023: € 1,820 k), comprises the capital reserve of € 11,461 k (Sep 30, 2023: € 11,461 k) as well as the statutory revenue reserves of € 5 k (Sep 30, 2023: € 5 k) and other revenue reserves of € 4,540 k (Sep 30, 2023: € 4,540 k).

Provisions decreased by € 692 k compared to the previous year to € 2,687 k (Sep 30, 2023: € 3,379 k). Pension provisions remained constant. Other provisions decreased to € 2,431 k, partly due to lower personnel provisions. Liabilities decreased mainly due to the reduction in liabilities to shareholders as at the balance sheet date by € 2,260 k to € 2,661 k (Sep 30, 2023: € 4,921 k). Deferred income increased by € 92 k to € 1,737 k due to higher customer prepayments for services to be rendered by the company in the future compared to the previous year.

The company's cash and cash equivalents decreased by € 2,871 k to € 4,872 k in the first half of the year.

Overall, the net assets, financial position and results of operations developed very satisfactorily.

## OPPORTUNITY AND RISK REPORT

There have been no significant changes to the company's risk situation since the beginning of the financial year. The disclosures made in the opportunity and risk report in the financial statements at the end of the financial year as at September 30, 2023 therefore continue to apply.

## FORECAST REPORT

At this point in time, we are sticking to our forecast: for the 2023/2024 financial year, sales are now expected to increase slightly year-on-year to between € 18.0 million and € 18.5 million. In addition to the slight increase in sales with the customer Hologic, sales in the lung and liver area are also expected to rise slightly. We expect a slight decline in the area of development services. For earnings before interest and taxes (EBIT), we expect stability in the range of € 4.5 million to € 5.0 million. The forecast slight growth in sales and the simultaneous increase in personnel costs and other operating expenses are key drivers for the EBIT outlook.

As in the previous reporting period, the Management Board will regularly review its expectations over the course of the 2023/2024 financial year on the basis of current business developments.

Bremen, May 27, 2024



Marcus Kirchoff

Sole Executive Board Member

# BALANCE SHEET

of MeVis Medical Solutions AG, Bremen, as of March 31, 2024

<b>ASSETS (IN €)</b>	<b>31.03.2024</b>	<b>30.09.2023</b>
<b>A. Fixed assets</b>		
<b>I. Intangible assets</b>		
Purchased concessions, industrial property rights and similar rights and assets as well as licenses to such rights and assets	0.00	0.00
<b>II. Property, plant and equipment</b>		
Operating and office equipment	305,693.13	146,057.36
<b>III. Financial assets</b>		
1. Shares in affiliated companies	299,805.00	312,042.00
2. Loans to affiliated companies	16,225,211.69	16,225,211.69
	<u>16,525,016.69</u>	<u>16,537,253.69</u>
	<u>16,830,709.82</u>	<u>16,683,311.05</u>
<b>B. Current assets</b>		
<b>I. Receivables and other assets</b>		
1. Trade receivables	2,355,159.69	2,651,876.35
2. Receivables from affiliated companies	681,356.33	616,184.59
3. Other assets	264,599.37	313,640.37
	<u>3,301,115.39</u>	<u>3,581,701.31</u>
<b>II. Cash on hand, bank balances</b>	<u>4,872,491.43</u>	<u>7,743,883.96</u>
	<u>8,173,606.82</u>	<u>11,325,585.27</u>
<b>C. Prepaid expenses and deferred charges</b>	<u>126,282.55</u>	<u>45,050.22</u>
	<u>25,130,599.19</u>	<u>28,053,946.54</u>



<b>LIABILITIES (IN €)</b>	<b>31.03.2024</b>	<b>30.09.2023</b>
<b>A. Equity capital</b>		
<b>I. Subscribed capital</b>		
Subscribed capital	1,820,000.00	1,820,000.00
<b>II. Capital reserve</b>	11,461,332.48	11,461,332.48
<b>III. Retained earnings</b>		
1. Legal reserve	5,000.00	5,000.00
2. Other retained earnings	4,539,688.30	4,539,688.30
	<u>4,544,688.30</u>	<u>4,544,688.30</u>
	<u>17,826,020.78</u>	<u>17,826,020.78</u>
<b>B. Provisions</b>		
1. Pension provisions	256.407.53	265,626.00
2. Tax provisions	0.00	165,134.47
3. Other provisions	2,430.506.84	2,948,630.92
	<u>2,686,914.37</u>	<u>3,379,391.39</u>
<b>C. Liabilities</b>		
1. Advance payments received on orders	7.920.67	14,512.82
2. Liabilities from deliveries and services	53.487.05	76,739.81
3. Liabilities to affiliated companies The company	2,661.393.29	4,920,981.90
4. Other liabilities	158.356.86	191,312.34
	<u>2,881,157.87</u>	<u>5,203,546.86</u>
<b>D. Prepaid expenses and deferred charges</b>	<u>1,736,506.17</u>	<u>1,644,987.51</u>
	<u>25,130,599.19</u>	<u>28,053,946.54</u>

## PROFIT AND LOSS ACCOUNT

of MeVis Medical Solutions AG, Bremen, for the period from October 1, 2023 to March 31, 2024

FIGURES IN €	2023/2024	2022/2023
1. Sales revenue	8,774,409.11	8,472,290.14
2. Other operating income	651,955.39	625,747.58
3. Cost of materials		
a) Expenses for purchased goods	34,506.89	35,425.01
b) Expenses for purchased services	<u>215,639.75</u>	<u>173,049.50</u>
	250,146.64	208,484.51
4. Personnel expenses		
a) Wages and salaries	4,249,997.73	3,971,064.53
b) Social security contributions and expenses for pensions and other employee benefits	<u>823,363.13</u>	<u>767,890.03</u>
	5,073,360.86	4,738,954.56
5. Amortization of intangible assets and depreciation of property, plant and equipment	63,320.55	47,521.16
6. Other operating expenses	1,947,141.62	2,834,330.65
7. Income from loans classified as financial assets	528,336.59	542,470.24
8. Other interest and similar income	114,708.13	81,894.23
9. Taxes on income and earnings	<u>74,046.26</u>	<u>64,099.60</u>
10. Earnings after taxes	2,661,393.29	1,829,011.71
11. Profit to be transferred on the basis of a profit transfer agreement	<u>2,661,393.29</u>	<u>1,829,011.71</u>
12. Profit for the period	<u>0.00</u>	<u>0.00</u>

# APPENDIX

of the half-year financial report of MeVis Medical Solutions AG, Bremen,  
as of March 31, 2024

## BASIC INFORMATION

### GENERAL INFORMATION

MeVis Medical Solutions AG has its registered office at Caroline-Herschel-Strasse 1 in 28359 Bremen, Germany and is entered in the commercial register at Bremen Local Court (HRB 23791 HB).

73.66 % of the share capital of MMS AG is currently held by Varex Imaging Deutschland AG, Willich. There is a domination and profit and loss transfer agreement between Varex Imaging Deutschland AG, as the controlling company, and MeVis Medical Solutions AG, as the controlled company. Through Varex Imaging Deutschland AG, MMS AG thus belongs to the Varex Group under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

MeVis Medical Solutions AG has prepared its annual financial statements for fiscal year 2022/2023 in accordance with the provisions of the German Commercial Code (HGB) applicable to corporations and in compliance with the German Stock Corporation Act (AktG). These interim financial statements were also prepared on this basis. These interim financial statements were neither reviewed nor audited in accordance with Section 317 HGB.

### ACCOUNTING AND VALUATION METHODS

In preparing the interim financial statements and determining the comparative figures for the previous year, the same accounting policies were applied as in the 2022/2023 annual financial statements. A detailed description of these methods is published in the notes to the 2022/2023 annual financial statements.

## SELECTED NOTES TO THE BALANCE SHEET AND INCOME STATEMENT

### 1. RECEIVABLES AND OTHER ASSETS

Trade receivables amounted to € 2,355 k as at the reporting date (Sep 30, 2023: € 2,652 k) and mainly relate to receivables from the customers Hologic, Adaptiv and Varian Medical Systems. All receivables have a remaining term of up to one year.

Receivables from affiliated companies relate in the amount of € 65 k (Sep 30, 2023: € 69 k) to trade with MBC KG and in the amount of € 616 k (Sep 30, 2023: € 547 k) to trade with Varex Imaging Deutschland AG, Willich and Varex Imaging Corporation, Salt Lake City, USA.

Other assets amounted to € 265 k as at the balance sheet date (Sep 30, 2023: € 314 k). These mainly relate to a rental deposit of € 250 k and receivables from a funding project.

### 2. PROVISIONS

Other provisions amount to € 2,431 k (Sep 30, 2023: € 2,948 k). Of this amount, € 695 k (Sep 30, 2023: € 613 k) relates to the defense against a patent lawsuit, € 609 k (Sep 30, 2023: € 733 k) to outstanding invoices, € 380 k (Sep 30, 2023: € 644 k) to bonus provisions, € 266 k (Sep 30, 2023: € 252 k) to vacation and overtime provisions, € 235 k (Sep 30, 2023: € 235 k) to warranty provisions and € 198 k (Sep 30, 2023: € 395 k) to provisions for the 13th salary.

### 3. LIABILITIES

In the reporting period, trade payables decreased by € 23 k and amounted to € 53 k as at the reporting date. The liabilities to affiliated companies of € 2,661 k (Sep 30, 2023: € 4,921 k) relate to the profit transfer based on the existing control and profit transfer agreement with Varex Imaging Deutschland AG. The liability does not legally arise until the end of the 2023/2024 financial year.

### 4. ACCRUALS AND DEFERRED INCOME

This item includes deferred revenue components from multi-component contracts that have already been paid but not yet realized. In addition, payments received from maintenance contracts are deferred if the corresponding maintenance service has not yet been performed.

### 5. SALES REVENUE

Sales are broken down into the following types of revenue:

FIGURES IN € K	01.10.2023 - 31.03.2024	01.10.2022 - 31.03.2023
Services (consulting and training)	3,338	3,341
Maintenance (software service contracts)	3,106	2,961
Software and licenses	2,330	2,170
	<b>8,774</b>	<b>8,472</b>

### 6. OTHER OPERATING INCOME

Other operating income amounted to € 652 k in the first half of the year (previous year: € 626 k). Of this, € 531 k (previous year: € 568 k) is mainly attributable to exchange rate differences. The exchange rate differences are due to the fact that the majority of services are invoiced in US dollars and liquidity is also held in US dollars. Due to the fact that the company is part of the Varex Imaging Group and in line with its corporate policy, no hedging transactions are concluded.

### 7. PERSONNEL EXPENSES

On average, 116 people were employed (same period of the previous year: 113), 111 of whom are permanent employees (same period of the previous year: 108). This corresponds to an average of 101 full-time equivalents (prior-year period: 100).

### 8. OTHER OPERATING EXPENSES

Other operating expenses amounted to € 1,947 k in the reporting period (previous year: € 2,834 k). They consist of expenses from exchange rate differences of € 742 k (previous year: € 1,739 k), rental expenses of € 259 k (previous year: € 252 k), expenses for legal, consulting and auditing services of € 228 k (previous year: € 217 k), selling expenses of € 106 k (previous year: € 129 k), operating expenses of € 59 k (previous year: € 64 k) and other operating expenses of € 560 k (previous year: € 433 k).

### 9. RELATIONSHIPS WITH RELATED PARTIES

The company conducts transactions with related parties, which are explained below. These are part of ordinary business activities and are treated as transactions with third parties.

Related parties include the jointly controlled companies MBC KG and MBC GmbH, Varex Imaging Deutschland AG and, via these, the affiliated companies of the Varex Group as well as the Management Board and the Supervisory Board and their close relatives.

The following receivables, liabilities, expenses and income of the company relate to related parties:

FIGURES IN € K	2023/2024
<b>Parent company</b>	
Receivables (from loans granted)	16,225
Receivables (from services)	103
Liabilities (from profit transfer agreement)	2,661
Income (mainly services and interest income)	1,048
Expenses (from profit transfer agreement)	2,661
<b>Other affiliated companies</b>	
Receivables (from services)	578
Income (mainly services and interest income)	1,435

## SUPPLEMENTARY REPORT

There were no business transactions of particular significance for the company after the balance sheet date.

## ASSURANCE OF THE LEGAL REPRESENTATIVE

"To the best of my knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim financial statements of MeVis Medical Solutions AG give a true and fair view of the assets, liabilities, financial position and profit or loss of MeVis Medical Solutions AG, and the interim management report includes a fair review of the development and performance of the business and the position of MeVis Medical Solutions AG, together with a description of the principal opportunities and risks associated with the expected development of MeVis Medical Solutions AG for the remaining months of the financial year."

Bremen, May 27, 2024

MeVis Medical Solutions AG

A handwritten signature in black ink, appearing to read "Marcus Kirchoff". The signature is written in a cursive style with a large, stylized 'K'.

Marcus Kirchoff

Sole Executive Board Member

# DISCLAIMER

## FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that are based on management's current estimates of future developments. Such statements are subject to risks and uncertainties that are beyond MeVis Medical Solutions AG's ability to control or estimate precisely, such as future market and economic conditions, the behavior of other market participants, the ability to successfully integrate acquired businesses and the actions of government regulators. Should any of these or other uncertainties and imponderables materialize, or should the assumptions on which these statements are based prove incorrect, actual results may differ materially from those expressed or implied by such statements. MeVis Medical Solutions AG does not intend or assume any obligation to update any forward-looking statements to reflect events or developments after the date of this report.

## DEVIATIONS FOR TECHNICAL REASONS

For technical reasons (e.g. conversion of electronic formats), there may be differences between the accounting documents contained in this financial report and those submitted to the Federal Gazette. In this case, the version submitted to the Federal Gazette is the binding version.

The financial report is also available in English; in the event of deviations, the German version takes precedence over the English translation.

The financial report is already available for download on the Internet at <http://www.mevis.de/de/investor-relations/finanzberichte/>

**MeVis Medical Solutions AG**

Caroline-Herschel-Str. 1  
28359 Bremen  
Germany

Phone +49 421 22495 0  
Fax +49 421 22495 999  
info@mevis.de

[www.mevis.de](http://www.mevis.de)